Synthesis and cytotoxic evaluation of novel brominated N-alkyl pyrano[3,2-c]quinolinones

Othman,E.S.; Jehan M. Morsy; Hany M. Hassanin; mohamed hassan, shrouk;

Abstract


A novel series of 6-alkyl-4-bromopyrano[3,2-c]quinoline-2,5-diones (2a–c),
6-alkyl-3,4-dibromopyrano[3,2-c]quinoline-2,5-diones (4a–c), and 6-alkyl-
3-amino-bromopyrano[3,2-c]quinoline-2,5-diones (6a–c) were synthesized via
appropriate conventional methods and in good yields. The structures of target
compounds were approved by elemental analysis, IR, 1H NMR, 13C NMR, and
mass spectrometry. The antitumor inhibitory activities of the new compounds
were evaluated on several cancer cell lines, A-549 (human lung cancer), HCT-
116 (human colon cancer), MCF-7 (breast cancer), and HePG-2 (human liver
cancer). Moreover, 50% inhibitory concentrations, IC50, were established.
5-Fluorouracil was used as a positive control in the viability assay. The screening
results showed that most of the examined compounds exposed powerful
inhibition activity toward various cell lines. Particularly, Compound 4c
exhibited higher cytotoxic activity against four tumor cell lines than the reference
drug, 5-fluorouracil, with significantly lower IC50 values. Accordingly,
most of the synthesized compounds would be a better prospective growth in
the anticancer drug discovery.


Other data

Title Synthesis and cytotoxic evaluation of novel brominated N-alkyl pyrano[3,2-c]quinolinones
Authors Othman,E.S. ; Jehan M. Morsy; Hany M. Hassanin; mohamed hassan, shrouk 
Keywords Pyranoquinolinones;Bromo;Antitumor;Cancer cell line;Cytotoxic activity
Issue Date 2021
Publisher Wiley
Journal J Heterocyclic Chem. 
Volume 58
Issue 1
Start page 305
End page 314
DOI 10.1002/jhet.4169

Attached Files

File Description SizeFormat Existing users please Login
jhet.4169.pdf2.2 MBAdobe PDF    Request a copy
jhet.4169.pdf2.15 MBUnknown    Request a copy
Recommend this item

Similar Items from Core Recommender Database

Google ScholarTM

Check



Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.